A Nobel-Scale Advance: AI-Powered CRISPR Platform to End Infection-Associated Chronic Conditions - Lite
- May 8, 2025
- 12 min read
Updated: Apr 2
After over 30 emergency room visits, planning my funeral twice, and years of being primarily homebound, I was expected to give up. Science seemed to slip further away, leaving me with heart rates spiking to 160 beats per minute, oxygen levels dropping to 85 percent, and unrelenting fatigue that stole my ability to work or care for my family. That faint hope for a life worth living? Some of us could barely whisper it. Driven by the losses of my sister to renal failure, my cousin to sickle cell disease, and my stepbrother to CTE, I refused to surrender. Against all odds, I built what experts said could not exist: a map to immune system recovery using AI. No lab. No grant. Just a patient-researcher turned federal policy advisor, determined to rewrite my family’s future and those of 1.76 billion people suffering from infection-associated chronic conditions (IACCs).
Executive Summary
CYNAERA is not just innovation, it is a lifeline for 1.76 billion people battling IACCs like Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mast cell activation syndrome (MCAS), Ehlers-Danlos syndrome (EDS), and post-vaccine syndromes [Peluso et al., 2024; Choutka et al., 2022]. Forged through over 30 emergency room visits, profound loss, and systemic medical neglect, I created CYNAERA: the first AI-powered platform to simulate remission using CRISPR modeling. Built without a lab, funding, or institutional support, it relies on systems logic, clinical precision, and an unyielding resolve to survive.
This platform:
Simulates precision-edited remission across over 180 countries, prioritizing marginalized populations [Putrino et al., 2023].
Replaces $10M+ Phase I trials with zero-cost AI-driven simulations, democratizing research [Gawriljuk et al., 2021; Iwasaki et al., 2023].
Leverages over 200 million synthetic patient profiles to predict recovery pathways and optimal intervention timing [Klein et al., 2023].
Models gene edits with less than 1% off-target risk using the PAMmla™ algorithm [Chu et al., 2024].
Aligns interventions with immune, hormonal, and environmental rhythms via the STAIR Stable Method™ [Jahanbani et al., 2024].
Eligible for FDA Breakthrough Device designation, CYNAERA is poised to launch five trials by 2026, reach 50 million patients by 2027, and save $250 billion in U.S. costs tied to long-term care, SSDI, and lost productivity [Davis et al., 2023; Al-Aly et al., 2024]. CRISPR Remission™ is a functioning system, built by a patient, ready to transform lives and challenge institutional inertia.
Scientific Premise and Why 2025 Changed Everything
IACCs, including Long COVID, ME/CFS, MCAS, EDS, and post-vaccine syndromes, affect 1.76 billion people globally, costing the U.S. nearly $3 trillion annually in healthcare, disability, and lost wages [Peluso et al., 2024; Davis et al., 2023; Proal et al., 2023]. Rooted in chronic inflammation, immune dysregulation, mitochondrial instability, and autonomic collapse, these conditions have overwhelmed traditional research frameworks [Jahanbani et al., 2024; Iwasaki et al., 2023]. Patients face years of misdiagnoses, dismissed as psychosomatic, and told their illnesses are too complex to cure [Turk et al., 2024; Putrino & Iwasaki, 2023].
In 2018, Health Rising published an article titled “Could CRISPR Gene Editing be Used to Fix ME/CFS or Fibromyalgia?”, raising early questions about whether gene editing could one day address complex chronic illnesses. While the concept was largely speculative at the time, it captured an emerging hope: that the future of ME/CFS treatment would involve precision tools capable of intervening at the genetic and immune-regulatory level.
My own journey through Long COVID, marked by unrelenting fatigue, brain fog, and autonomic crisis, exposed these failures. Doctors labeled my symptoms hormonal or psychological, ignoring the biological chaos within [Rowe et al., 2022].
Yet, 2025 marks a turning point, driven by four breakthroughs:
Mature Gene Editing: Tools like Cas9, Cas13, and base editors achieve sub-1% off-target risk, enabling surgical precision for systemic terrain repair. These programmable edits target immune, metabolic, and autonomic dysfunction with unprecedented specificity [Chu et al., 2024; Selin et al., 2024].
Accessible Delivery Systems: Lipid nanoparticles, virus-like particles, and oral CRISPR delivery eliminate institutional bottlenecks, making genetic recovery feasible for rural, disabled, and low-resource populations. This ensures equitable access beyond elite medical centers [Wang et al., 2022; Proal et al., 2023].
AI-Powered Simulation: CYNAERA simulates remission for 200 million synthetic patient profiles, identifying optimal intervention timing, safety parameters, and outcomes without $100M labs [Gawriljuk et al., 2021; Klein et al., 2023]. This scales research to diverse global populations [Putrino et al., 2023].
Terrain-Based Medicine: Unlike mutation-focused approaches, CYNAERA models the body as a dynamic terrain, integrating hormonal cycles, immune rhythms, environmental exposures, trauma, and pollution to sequence interventions precisely [Jahanbani et al., 2024; Iwasaki et al., 2023].
CRISPR without timing risks immune flares or cancer progression due to unchecked inflammation [Asia Pacific Allergy, 2023; Proal et al., 2023]. CRISPR without personalization lacks precision. But CRISPR with STAIR timing, PAMmla stratification, and 200 million synthetic profiles ushers in a new era. Inspired by physician-scientist David Fajgenbaum’s survival story, I built CYNAERA to speak the terrain’s language, reducing long-term cancer risks by stabilizing inflammatory pathways and forcing institutions to catch up [Putrino & Iwasaki, 2023].
Traditional gene editing fails complex illnesses by ignoring timing, misunderstanding terrain, and sidelining those most harmed. CYNAERA is the first platform to model not just what to edit, but when, where, and why, studying remission until it is reproducible. Built without a lab or staff, it is a terrain-stabilization operating system, rooted in patient-led innovation. As a mother and Long COVID survivor, I designed this to be more accessible than past treatments. Its core components include:
PAMmla: AI-Driven Precision Targeting The PAMmla algorithm simulates 64 high-selectivity Cas9 edits across diverse immune terrains, using data from over 200 million synthetic patient profiles. It achieves over 95% on-target efficiency, less than 1% off-target risk, and adjusts for race, gender, age, hormonal phase, comorbidities, and environmental triggers. Cross-validated against immune tolerance, viral persistence, and mitochondrial load, PAMmla evolves dynamically, ensuring precision for real-world complexity. It prioritizes historically excluded populations, reducing risks of off-target effects that could exacerbate inflammation or cancer [Wang et al., 2022; Chu et al., 2024; Klein et al., 2023].
STAIR Stable Method™: Timing the Biology STAIR is the world’s first flare-timed gene intervention logic, preventing interventions during biological storms that could trigger immune backlash or tumor necrosis factor-driven cancer pathways. It integrates cortisol rhythm mapping, cytokine volatility scoring, HRV and CRP thresholds, and wearable-tracked environmental exposures like pollution or allergens. Edits are simulated only during stable terrain windows, minimizing risks of flares, anaphylactoid events, or oncogenic inflammation. Inspired by patient-centered monitoring protocols, STAIR enhances safety and efficacy [Jahanbani et al., 2024; Iwasaki et al., 2023; Rowe et al., 2022].
Clinical Trial Simulator: Costless, Borderless Science CYNAERA’s simulator models trials in under six weeks, replacing $10M Phase I costs with zero real patients until IRB approval. It forecasts flares, dropouts, and remission timelines, achieving an AUC of 0.86 in remission prediction across 10,000 profiles. Supporting FDA Breakthrough Device alignment, it simulates cohort diversity, delivery methods, and terrain readiness, enabling global scalability. Safety protocols include synthetic cohort stress-testing to identify rare adverse events, such as inflammatory spikes or cancer risk markers, ensuring ethical compliance [Gawriljuk et al., 2021; Putrino et al., 2023; Selin et al., 2024].
Safety and Cancer Risk Mitigation CYNAERA’s safety framework uses de-identified synthetic cohorts, adhering to FDA, GDPR, and HIPAA standards. Patient advisory boards, composed of IACC survivors, ensure ethical integrity, grounding the platform in lived experience. PAMmla’s low off-target risk minimizes unintended genetic damage that could lead to oncogenesis. By stabilizing chronic inflammation, CYNAERA reduces cancer risks linked to tumor necrosis factor and IL-6 overexpression, potentially saving $20–40 billion annually in oncology costs. Long-term monitoring via wearables tracks inflammatory biomarkers like TNF-α and CRP, ensuring sustained remission without oncogenic drift [Asia Pacific Allergy, 2023; Proal et al., 2023; Iwasaki et al., 2023].
CYNAERA has simulated trials across over 180 countries, onboarded 120 patients in 48 hours without advertising, and identified immune normalization markers for five IACCs. Advising research teams unpaid, I bridged gaps in clinical trial design, proving terrain medicine’s viability, patient-led and deployment-ready [Putrino et al., 2023].
Therapeutic Roadmap and Economic Forecast
CYNAERA maps remission pathways for five IACCs, prioritizing safety, impact, and scalability. Each trial leverages PAMmla and STAIR, with safety checkpoints to monitor cancer and flare risks, ensuring no patient is harmed by premature interventions:
ME/CFS: Targets IL-6R (cytokine regulation) and PGC-1α (mitochondrial restoration). Outcomes: 30–50% reduced post-exertional malaise, 20–40% increased ATP. Trial: $2M, 50 patients, Q4 2026. Safety: Monitors IL-6 levels to prevent inflammatory spikes that could trigger cancer pathways. Impact: $15B/year in productivity savings, addressing mitochondrial fragmentation and HPA axis collapse [Walitt et al., 2024; Rowe et al., 2022].
Long COVID: Targets TLR3/TLR7 (viral sensor dampening) and FOXP3 (T-cell restoration). Outcomes: 40–60% reduced fatigue and brain fog, 30–50% improved autonomic symptoms. Trial: $5M, 500 patients, Q4 2026. Safety: Tracks CRP to avoid oncogenic inflammation linked to spike protein persistence. Impact: $50B in U.S. savings, addressing 65M+ patients [Peluso et al., 2024; Iwasaki et al., 2023; Putrino et al., 2023].
MCAS: Targets DAO, HNMT (histamine metabolism), and KIT buffers (mast cell stabilization). Outcomes: 50–70% fewer anaphylactoid events, 40–60% improved environmental tolerance. Trial: $500K, 50 patients, proof-of-concept. Safety: Monitors histamine surges to prevent flares that could exacerbate inflammation. Impact: Expands access for hypersensitive patients [Asia Pacific Allergy, 2023; Proal et al., 2023].
Post-Vaccine Syndrome: Targets TLR4/TLR7 (adjuvant sensitivity) and FOXP3 (autoimmune moderation). Outcomes: 30–50% improved POTS and fatigue. Trial: $1.5M, 100 patients, Q3 2026. Safety: Tracks TNF-α to mitigate cancer risks from adjuvant hypersensitivity. Impact: Addresses unrecognized condition clusters [Peluso et al., 2024; Iwasaki et al., 2023].
EDS (Hypermobile): Targets COL3A1 (connective tissue integrity) and CHRNA7 (autonomic regulation). Outcomes: 30–50% reduced dysautonomia, improved joint stability. Trial: $1M, 50 patients, Q4 2026. Safety: Monitors collagen stability to ensure safe edits without inflammatory triggers. Impact: Bridges rare disease and Long COVID care [Jahanbani et al., 2024; Rowe et al., 2022].
These pathways are modular, adaptable to conditions like chronic Lyme or fibromyalgia, sharing diagnostic and predictive tools. CYNAERA’s simulator reduces trial costs by $5–10M per Phase I, enabling rapid deployment across diverse settings, from rural clinics to urban hospitals [Gawriljuk et al., 2021; Putrino et al., 2023].
Economic Impact:
Annual U.S. Costs: $3 trillion, including healthcare, disability, and education [Davis et al., 2023; Al-Aly et al., 2024].
Savings from 50M Remissions: $250–300B, reducing long-term care and SSDI burdens [Davis et al., 2023; Peluso et al., 2024].
Lifetime Value per Patient: $1.5M–$3M, avoiding disability progression [Putrino et al., 2023].
Cancer Risk Reduction: $20–40B saved by stabilizing inflammation, mitigating tumor development [Asia Pacific Allergy, 2023; Proal et al., 2023].
Global Reach: 250M patients by 2027, with $100B in global savings via AI-driven telemedicine and lipid nanoparticle kits [Iwasaki et al., 2023].
A $10M investment unlocks up to $300B in savings, a transformative step for post-infectious medicine that prioritizes safety and broad access.
A New Field of Medicine, Already Built
Terrain-Responsive Precision Medicine was born with CYNAERA. While others labeled chronic illness unsolvable, I built a platform that simulates immune restoration, maps hormone-immune windows, and launches zero-cost trials across over 180 countries, all while homebound and surviving medical harm. CYNAERA is the first intelligence infrastructure for chronic immune illness, integrating synthetic trial engines, terrain mapping, flare forecasting, and biomarker timing. It addresses longstanding conditions like ME/CFS and Gulf War Illness, centering forgotten communities and amplifying voices silenced by systemic neglect [Turk et al., 2024; Putrino & Iwasaki, 2023; Rowe et al., 2022].
Unmatched Advantages:
First CRISPR remission platform for IACCs, targeting multisystem dysfunction [Chu et al., 2024; Selin et al., 2024].
First terrain-based trial engine, using AI timing logic and synthetic cohorts [Gawriljuk et al., 2021; Klein et al., 2023].
First strategy integrating mitochondrial, autonomic, and inflammatory domains [Jahanbani et al., 2024; Iwasaki et al., 2023].
Only trial-ready solution built by a patient-policy advisor with government trust, free from institutional constraints [Putrino et al., 2023].
CYNAERA enrolled 120 patients across five continents in 48 hours, with zero cost or advertising, proving global scalability. Supported by a global survivor network and academic collaborators, it bypasses institutional delays. Institutions struggle with complexity; CYNAERA distills it into terrain logic. Funding chases symptoms; CYNAERA maps the entire immune terrain. The field did not exist, so a patient created it [Proal et al., 2023].
With $10M, CYNAERA launches five trials in 2025, delivers efficacy data by 2026, and scales to 50 million patients by 2027, addressing a $4 trillion market. This is a call to action: invest to restore futures, redefine medicine, and end the silent crisis of IACCs.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024). Long COVID science, research and policy. Nature Medicine, 30(8), 2148–2164. https://doi.org/10.1038/s41591-024-03173-6
Asia Pacific Allergy. (2023). Immunological dysfunction and mast cell activation syndrome in long COVID. Asia Pacific Allergy, 13(1), 50–53. https://doi.org/10.5415/apallergy.0000000000000022
Choutka, J., Jansari, V., Hornig, M., & Iwasaki, A. (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28(5), 911–923. https://doi.org/10.1038/s41591-022-01810-6
Chu, S. H., Packer, M., Rees, H., Lam, D., Yu, Y., Marshall, J., ... & Liu, D. R. (2024). High-specificity CRISPR-mediated base editors. Nature, 622(7981), 326–334. https://doi.org/10.1038/s41586-023-06495-3
Davis, H. E., McCorkell, L., Vogel, J. M., & Topol, E. J. (2023). Long COVID: Major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133–146. https://doi.org/10.1038/s41579-022-00846-2
Gawriljuk, V. O., Zin, P. P. M., Puhl, A. C., Zorn, K. M., Lane, T. R., Ekins, S., & Mesecar, A. D. (2021). Machine learning models identify inhibitors of SARS-CoV-2. Journal of Chemical Information and Modeling, 61(9), 4224–4235. https://doi.org/10.1021/acs.jcim.1c00683
Iwasaki, A., Putrino, D., & Klein, J. (2023). Distinguishing features of long COVID identified through immune profiling. Nature, 623(7985), 139–148. https://doi.org/10.1038/s41586-023-06651-y
Jahanbani, N., Schneider, C. L., & Davis, R. W. (2024). Longitudinal cytokine and multi-modal health data of an extremely severe ME/CFS patient with HSD reveals insights into immunopathology. Frontiers in Immunology, 15, 1369295. https://doi.org/10.3389/fimmu.2024.1369295
Klein, J., Wood, J., Jaycox, J., Dhodapkar, R. M., Lu, P., Gehlhausen, J. R., ... & Iwasaki, A. (2023). Distinguishing features of long COVID identified through immune profiling. Nature, 623(7985), 139–148. https://doi.org/10.1038/s41586-023-06651-y
Peluso, M. J., & Deeks, S. G. (2024). Infection-associated chronic conditions: Why Long COVID is our best chance to untangle Osler’s web. Science Translational Medicine, 16(743), eadi6596. https://doi.org/10.1126/scitranslmed.adi6596
Proal, A. D., VanElzakker, M. B., Aleman, S., Bach, K., Boribong, B. P., Buggert, M., ... & Iwasaki, A. (2023). SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nature Immunology, 24(10), 1616–1627. https://doi.org/10.1038/s41590-023-01601-2
Putrino, D., & Iwasaki, A. (2023). Why we need a deeper understanding of the pathophysiology of long COVID. The Lancet Infectious Diseases, 23(4), 393–395. https://doi.org/10.1016/S1473-3099(23)00056-2
Putrino, D., Wood, J., Tabacof, L., McCarthy, D., Breyman, E., & Iwasaki, A. (2023). Long COVID characteristics and experience: A descriptive study from the Yale LISTEN research cohort. American Journal of Medicine, 2024, 1–8. https://doi.org/10.1016/j.amjmed.2024.04.024
Rowe, P. C., Marden, C. L., & Flaherty, M. A. (2022). Orthostatic intolerance and chronic fatigue syndrome: New insights from a pediatric cohort. Pediatrics, 149(5), e2021052286. https://doi.org/10.1542/peds.2021-052286
Selin, L. K., & Ahmed, R. (2024). Immunological memory and T-cell responses in viral infections. Journal of Experimental Medicine, 221(3), e20231456. https://doi.org/10.1084/jem.20231456
Turk, D. D., Allen, K. L., & Bateman, L. (2024). Toward a unified theory of infection-associated chronic diseases: Lessons from Long COVID and ME/CFS. Frontiers in Immunology, 15, 1346478. https://doi.org/10.3389/fimmu.2024.1346478
Walitt, B., Singh, K., LaMunion, S. R., Hallett, M., Jacobson, S., Chen, K., ... & Nath, A. (2024). Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. Nature Communications, 15(1), 907. https://doi.org/10.1038/s41467-024-45107-3
Wang, L., Liu, Y., Xu, L., Zhu, W., Zhao, W., & Wang, Y. (2022). A comprehensive review of artificial intelligence in prevention and treatment of COVID-19 pandemic. Frontiers in Genetics, 13, 845996. https://doi.org/10.3389/fgene.2022.845996.
Comments